• The Medicines Co., of Parsippany, N.J., reported 2012 net revenue increased by 15.2 percent, to $558.6 million, from $484.7 million in 2011. U.S. net revenue from anticoagulant Angiomax (bivalirudin) increased by 10.9 percent, to $501.7 million, compared with $452.3 million in 2011, while international net revenue from the drug, branded Angiox outside the U.S., jumped by 47.4 percent, to $46.5 million, compared with $31.6 million in 2011.